First licensed treatment for hidradenitis suppurativa

The licence for Humira (adalimumab) has been extended to include the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults who have had an inadequate response to conventional HS therapy

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days
  • Join GPOnline now and pay nothing for the first 30 days

Sign Up Sign Up